Upon completion of this course, the participant will be able to:
- Describe emerging surgical therapies in heart failure; in particular, mechanical cardiac support, mitral valve repair and myoblast transfer.
- Discuss new guidelines from ATPIII study and explain the new risk assessment tool being used to determine appropriate lipid levels.
- Discuss how the changes will affect our treatment of elevated cholesterol levels in high-risk patients.
- Discuss the evolution of aortic stenosis treatment, including surgical vs. percutaneous replacement (including risks and benefits of each).
- Explain risk stratification and decision-making for the high-risk patient.
- Assess current guidelines for the treatment of PAD.
- Explain specific supportive measures for cardiac conditions at end of life and how care of the heart failure patient has evolved over time.
- Identify steps toward a healthy life and how this has evolved over time.
- Explain treatment methods for endocarditis and the evolution of treatment changes.
- Identify the different classes of anticoagulants and antiplatelet drugs including heparin, unfractionated heparin and direct thrombin inhibitor, and discuss complications of these drugs including heparin induced thrombocytopenia.